Feb 13 2007
Avista Capital Partners, a leading private equity firm, announced today it has signed a definitive agreement to acquire BioReliance Corporation, a business unit of Invitrogen Corporation (Nasdaq: IVGN) for approximately $210 million.
BioReliance is a contract service organization providing biological safety testing, toxicology, viral manufacturing, and laboratory animal diagnostic services to the pharmaceutical and biopharmaceutical industries globally.
|
